Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CEF 101: Don’t Buy Funds At Abnormal Premiums

Page 1 of 2

Investors in closed-end funds have to contend with different risks and analysis criteria than ETF or open-ended mutual funds.  Those that have spent any length of time in this space have more than likely learned how important it is to look beyond distribution yield, recent price trend, or the touch of a star fund manager.  While these characteristics are important, they can easily be overridden by an exorbitant premium or fundamental catalyst that turns the corner.

A recent example of this phenomenon comes in the form of the popular Doubleline Opportunistic Credit Fund (NYSE:DBL).  This fund was the first closed-end vehicle to be released by Jeffrey Gundlach at DoubleLine Capital in 2012.  It has thrived under the stewardship of his investment committee, posting average annualized market price returns of +12.00% from inception through 8/31/16.

The strategy is essentially a leveraged off shoot of Gundlach’s other flagship fixed-income strategies.  It carries a high degree of mortgage-backed security exposure with flexibility in risk management and/or sector positioning.

As you can see on the 1-year chart below, the share price of DBL really started to shoot higher versus its underlying net asset value (NAV) near the end of 2015.  This peaked with a premium of greater than 17% in September 2016 despite the fact that the NAV has essentially traveled a sideways path.


More recently, the uptick in interest rates, combined with the flighty nature of closed-end fund investors, caused a sharp correction in DBL’s market price.  The fund is now trading at just a 5.41% premium to its NAV as of October 13 (according to Morningstar data).  That 12% decline in market value came with little fluctuation of the underlying portfolio holdings.

Furthermore, investors who were aggressively purchasing DBL throughout 2016 should have been aware that this rising premium was somewhat of an abnormality.  The 3-year average premium for this fund is listed at +4.88% and it has even traded at a discount several times between 2013 and 2015.  This skewed risk profile should have set off alarm bells for those who were paying attention to these relative valuation metrics.

Follow Doubleline Opportunistic Credit Fund (NYSE:DBL)
Trade (NYSE:DBL) Now!

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!